Biotech · Private company · San Francisco, CA, US
Ossium Health, Inc.
Track this companyFree. Adds Ossium Health, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials85 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- Ossium HPC Marrow, Bone Marrow TransplantPhase 2 · Acute LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Post-transplant treatmentPhase 2 · Acute LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Pre-transplant conditioning - Myeloablative (MAC)Phase 2 · Acute LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Pre-transplant conditioning - Reduced Intensity (RIC)Phase 2 · Acute LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)Bone Marrow Transplant (BMT)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)RECRUITING · started Dec 22, 2024ClinicalTrials.gov NCT06752577 · fetched Nov 12, 2026
- A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic MalignanciesPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 16, 2024ClinicalTrials.gov NCT05589896 · fetched Nov 12, 2026
- HPC Offered for PRESERVE ExpansionRECRUITING · started Jun 27, 2024ClinicalTrials.gov NCT07145411 · fetched Nov 12, 2026
- Delayed Tolerance Through Mixed ChimerismPHASE1_PHASE2 · RECRUITING · started Oct 1, 2023ClinicalTrials.gov NCT05900401 · fetched Nov 12, 2026
- Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent AsthmaPHASE1 · TERMINATED · started Mar 16, 2022ClinicalTrials.gov NCT05035862 · fetched Nov 12, 2026
- Study of Ossium Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in the Setting of Crohn's DiseasePHASE1_PHASE2 · TERMINATED · started Feb 1, 2022ClinicalTrials.gov NCT05075811 · fetched Nov 12, 2026
- Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host DiseasePHASE1 · TERMINATED · started Dec 2, 2021ClinicalTrials.gov NCT04328714 · fetched Nov 12, 2026
- Using T-Cell Alloreactivity and Chimerism to Guide Immunosuppression Minimization in Intestinal TransplantationPHASE1 · RECRUITING · started Oct 22, 2021ClinicalTrials.gov NCT04804891 · fetched Nov 12, 2026
NIH awards3
- Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injuryFiscal year 2026 · $580KNIH RePORTER 5R44AI183961-03 · fetched Nov 12, 2026
- Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injuryFiscal year 2025 · $1MNIH RePORTER 5R44AI183961-02 · fetched Nov 12, 2026
- Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injuryFiscal year 2024 · $375.1KNIH RePORTER 1R44AI183961-01A1 · fetched Nov 12, 2026